Search databaseBooksAll DatabasesAssemblyBiocollectionsBioProjectBioSampleBioSystemsBooksClinVarConserved DomainsdbGaPdbVarGeneGenomeGEO DataSetsGEO ProfilesGTRHomoloGeneIdentical Protein internet CatalogNucleotideOMIMPMCPopSetProteinProtein ClustersProtein family ModelsPubChem BioAssayPubChem CompoundPubChem SubstancePubMedSNPSRAStructureTaxonomyToolKitToolKitAllToolKitBookgh Bookshelf. A company of the national Library the Medicine, national Institutes of Health.

You are watching: Do you have to get vaccines in the military

Institute of medicine (US) Committee top top a Strategy for Minimizing the influence of Naturally occurring Infectious conditions of armed forces Importance: Vaccine concerns in the U.S. Military; Lemon SM, Thaul S, Fisseha S, et al., editors. Protecting our Forces: boosting Vaccine acquisition and access in the U.S. Military. Washington (DC): national Academies push (US); 2002.


Protecting our Forces: boosting Vaccine salvation and accessibility in the U.S. Military.

Show details
Institute of medicine (US) Committee top top a Strategy for Minimizing the affect of Naturally developing Infectious conditions of armed forces Importance: Vaccine problems in the U.S. Military; Lemon SM, Thaul S, Fisseha S, et al., editors.

The department of Defense (DoD) administers 17 various vaccines, as outlined in the share Instruction ~ above Immunizations and also Chemoprophylaxis (Secretaries that the waiting Force, Army, Navy, and also Transportation, 1995), because that the avoidance of transmittable diseases amongst military personnel, wherein appropriate. The vaccines room administered to military personnel top top the basis of army occupation, the location of the deployment, and also mission requirements. In this chapter, the committee reviews information on the current availability of vaccines come DoD and also describes vital projects in DoD"s vaccine advance pipeline.


Table 3-1 provides an introduction of the major infectious an illness threats come U.S. Armed forces personnel and also displays even if it is the ideal vaccine product is obtainable for military use, is licensed in the United states by the Food and Drug management (FDA), is one investigational new drug (IND), or is in development. That is an incomplete list of potential threats and also does not encompass a number of infectious illness or infectious disease agents for which a vaccine is neither obtainable nor in development, but against which the military might have a require for a vaccine, such as Crimean-Congo hemorrhagic fever, West Nile encephalitis, Nipah virus, Norwalk virus, Lassa fever, and also other typical infections or infectious condition agents, such as gonorrhea, chlamydia, and also tuberculosis. The info presented in the tables that follow are based upon material detailed by the U.S. Military Medical Research and also Materiel Command (USAMRMC), FDA, and the pharmaceutical Research and Manufacturers that America (PhRMA) websites, as well as presentations made to the committee.


The committee is not mindful of a standard definition of the term “vaccine availability” or of any type of threshold because that determining whether a vaccine need to be taken into consideration available. Part vaccines are obtainable only through complicated and unusual procedures or circumstances. For example, one-of-a-kind operations troops may be at danger for smallpox, and in such situations arrangements need to be made to transfer the smallpox vaccine indigenous the Centers for an illness Control and Prevention (CDC) to DoD.1 part vaccines are produced in small pilot lots and also are obtainable as INDs through DoD"s special Immunizations regime (SIP) to “individuals who have actually a high work-related risk—laboratory workers, infrastructure inspectors, vaccine manufacturers and certain military response teams” (Boudreau and also Kortepeter, 2002). The precision shown in Tables 3-1 come 3-5 by the use of dichotomies such as “limited availability” or “unavailable,” although beneficial as one overview, belies a fluid and complex actuality. At a minimum, the names of the manufacturers keep an altering as corporate reality merge, grow, or realign themselves. Global coordination is compelled for part vaccines that room manufactured external of the joined States however licensed in the United claims by FDA. Others space manufactured and licensed external the unified States, presenting different and also usually more complex acquisition problems.



Vaccines Administered together INDs That space No much longer Being Produced and also That are of limited Availability.

Nonetheless, the 51 infectious disease threats provided in Tables 3-2 through 3-5 space classified follow to the accessibility of related, particular vaccine commodities or other organic countermeasures. Special, Table 3-2 list vaccines that room licensed and also generally accessible for usage by DoD personnel. It additionally lists the number of manufacturers involved. Table 3-2 displayed that many of this vaccines are made by solitary suppliers and thereby says the fragility that the vaccine supply crucial to military readiness. Table 3-3 list vaccines the were previously licensed by FDA however that are no longer available to DoD. This list has vaccines versus smallpox and also plague, further depicting the equipped forces" vulnerability come potential organic warfare agents. Tables 3-4 and 3-5 list vaccines that, although never licensed through FDA, have at times been easily accessible for DoD use as assets with IND status. Table 3-4 lists those vaccines the are available only under the restrictive regulations governing the usage of assets with IND status, whereas Table 3-5 perform the subset of assets that are no longer produced however that are accessible to a minimal number of military personnel as INDs v DoD"s SIP.



FDA-Licensed Vaccines and Related Biologics obtainable to U.S. Army Personnel.



Selected Vaccines formerly Licensed by FDA yet Not Available.


Vaccines easily accessible to U.S. Armed forces Personnel together IND Products.

Many that the special-use vaccines the were when licensed or used by the army as commodities with IND status are no much longer available. This situation arises as a result of any kind of of a selection of obstacles. For many vaccines that are products with IND status, there was merely insufficient resources for advanced development. For various other products, it was deemed difficult, if not impossible, to demonstrate their effectiveness and also safety in humans, thus avoiding the possibility of their licensure. Sector factors, such as insufficient sustained demand, space obstacles as room a absence of attention or monetary incentive for industry to get involved in the development or scale-up that the production process, the lack of an adequate physical infrastructure to fulfill the regulatory demands for manufacture of the vaccine, or the i can not qualify of manufacturers to meet other regulatory requirements. The last 3 factors likewise illustrate the importance of the shift from the production of pilot several a vaccine to scale-up of production to a level for clinical use of the vaccine by bigger numbers the people. This transition requires the a manufacturer (1) have the technical ability to produce the vaccine, the physical facilities to develop the vaccine, and the personnel to draw away toward manufacturing of the vaccine; (2) possess suffer with the regulatory and clinical research study affairs necessary to effectively license a vaccine; and also (3) have actually the financial motive to communicate in the long, arduous, and expensive licensing process in the challenge of uncertain earnings in the end. Time and again, these components have limited the engagement that the most experienced vaccine manufacturers in the production and licensure of brand-new vaccines, an especially special-use vaccines for use by the military.


Table 3-6 provides an overview of USAMRMC"s infectious disease research program, reflecting the Joint technology Coordinating Group-2 (JTCG-2)2 priority ranking and the funding obtainable to each study activity. Brief descriptions that the current status that the pick vaccine research programs supported by the Military transmittable Diseases Research program (MIDRP)3 show up in the complying with paragraphs.


USAMRMC budget Year (FY) 2001 routine Priorities, in diminish JTCG-2–Assigned Rank, and also FY 2000 investment in Exploratory Research.

Malaria Vaccine

Growing resistance come antimalarial drugs has actually increased the urgency that the malaria vaccine effort. A candidate Plasmodium falciparum vaccine— RTS,S4 —has to be in advance for more than a decade by SmithKline Beecham Biologicals (now part of GlaxoSmithKline ) and also DoD. RTS,S combines the hepatitis B virus surface antigen through a circumsporozoite recombinant protein as a virus-like fragment formulated v the proprietary adjuvant system AS02. In clinical trials, this vaccine was demonstrated to defend U.S. Volunteers versus P. Falciparum malaria and also protected 70 percent that semi-immune adults in a field trial carried out in The Gambia, albeit for only 2 months (Bojang et al., 2001; Stoute et al., 1997). The joint initiatives of DoD and GSK are intensified by a partnership through the Malaria Vaccine Initiative at the program for Appropriate an innovation in Health5 that is allowing evaluation the the vaccine for usage in children. A phase I6 trial is being performed in The Gambia, and a phase II psychological is planned because that Mozambique in 2002 (GSK, 2001; MVI, 2001). In 1998, a parallel navy regimen reported the safety of a candidate DNA-based vaccine and also its capacity to elicit killer T cells with specificity for malaria peptides. The navy and its partners through which it has cooperative Research and advancement Agreements (CRADAs), Vical and also Aventis, are currently constructing and also testing more facility vaccines. In November 2001, Vical and also the U.S. Naval clinical Research center announced the outcomes of phase II clinical trials. The trials shown that the candidate vaccine was safe and also well tolerated.

Vaccines against Diarrheal Diseases

Current research tasks directed in ~ protecting armed forces personnel and also travelers versus the most common varieties of diarrheal illness by use of vaccines target some of the bacter agents of those diseases, in particular, Campylobacter, enterotoxigenic Escherichia coli (ETEC), and also Shigella. Numerous candidate vaccines space in development, although this efforts face many challenges, including the huge number the serologically distinct varieties of these organisms bring about diarrhea and also the difficulty of inducing a mucosal immune solution capable of impede infection v enteric pathogens. A candidate Shigella flexneri vaccine emerged at the Institut Pasteur and manufactured at Walter Reed military Institute of research (WRAIR) pilot lot manufacturing facility was first tested in healthy and balanced volunteers in ~ the U.S. Military Medical research study Institute for transmittable Diseases (USAMRIID) in 1996. A larger trial v 100 or much more U.S. Volunteer is planned for later on in 2002. A step II clinical trial including 200 to 300 Bangladeshi youngsters to test the vaccine"s efficacy in an environment where the an illness is endemic is likewise planned (USAMMDA, 2001b). Vaccines against other species of the genus Shigella—Shigella sonnei and Shigella dysenteriae—are also being evaluated.

A vaccine designed to protect versus ETEC is under review in Egypt, and brand-new vaccines based on microencapsulated ETEC antigens space under development. A Campylobacter vaccine is in progressed development, yet it is likely that new approaches will certainly be compelled to do the vaccine much more effective. Market partnerships supporting the research include a DoD Dual-Use science & an innovation program contract v Acambis, Inc. To construct Campylobacter and also ETEC vaccines (Acambis, Inc., 2001), a CRADA with Antex Biologics, Inc. To build Campylobacter vaccines (USAMMDA, 2001c), and also a little Business creation Research program grant from the national Institute the Allergy and also Infectious illness to build oral microbead vaccines versus diarrhea. Antex Biologics, Inc. Is likewise researching the opportunity of a multivalent vaccine to avoid diarrhea resulted in by S. Flexneri, S. Sonnei, Campylobacter jejuni, and ETEC (Antex Biologics, Inc., 2001).

Dengue Vaccine

DoD scientists have actually a long background of experience with dengue vaccines and the advance of diagnostic tests for dengue (Innis et al., 1988; Kanesa-thasan et al., 2001; Vaughn et al., 1996). WRAIR and GSK have operated to construct a tetravalent vaccine the is being evaluated in a phase II clinical attempt in Thailand (Innis, 2001; WHO, 2002).

Hepatitis E Vaccine

Epidemiological research studies by CDC, the army, the navy, and scientists in Russia, Pakistan, Nepal, and other nations have presented that the hepatitis E virus (HEV) is the most common reason of hepatitis in adult in many emerging countries (Clayson et al., 1998). Genelabs, Inc., in participation with CDC, isolated and also cloned HEV (Genelabs Technologies, 2001). Investigators at the nationwide Institutes of wellness (NIH) arisen a baculovirus-expressed recombinant protein candidate HEV vaccine in the late 1990s; that vaccine, occurred at NIH, is license is granted to GSK. Two Phase ns clinical trials—one in the united States and also one in Nepal—have been carried out through a joint effort of NIH, DoD, Genelabs Technologies, and GSK. A step II clinical psychological of the vaccine with 2,000 adult volunteers is under method in Nepal (Genelabs Technologies, 2001).

Meningococcal team B Vaccine

The initiatives of investigators in ~ WRAIR brought about the advancement of a quadrivalent polysaccharide meningococcal vaccine that has actually been recommended for use by selected civilian populations, such as college student (AAP, 2000; CDC, 2000b). Efforts to construct a meningococcal group B vaccine continue, yet such a vaccine has proved more difficult to construct (Brundage and also Zollinger, 1987; Jódar et al., 2002). Although number of promising candidate vaccines based upon outer membrane protein procedures of the team B meningococcus have proceeded come large-scale field trials, no licensed product is yet obtainable in the unified States.

HIV Vaccine

The goal of the U.S. Armed forces HIV research Program7 is to develop a vaccine that gives protection versus all recognized subtypes the HIV type 1 (HIV-1) circulating transparent the world. Initiatives to day have concentrated on (1) monitoring for decision of the HIV subtypes infecting U.S. Forces; (2) characterization of widespread subtypes of HIV-1 around the world, including genetic recombinants; (3) collaborative initiatives with commercial partners to architecture vaccine constructs based on a large array the subtypes, consisting of both those widespread in the unified States and those prevalent in other regions of the world; (4) preparation of ar sites in Thailand and Uganda for testing of a vaccine; and also (5) conduct of beforehand clinical safety and immunogenicity studies in Thailand, Uganda, and the joined States. The program has actually candidate vaccines—including those that usage naked DNA, vectored DNA, and recombinant protein from HIV subtypes E, A, D, and C—in various stages of advance and testing. A step III clinical trial, in cooperation with the to adjust of Public health and wellness of Thailand, is booked to start in autumn 2002 for evaluation of a vaccine consists of a canarypox virus vector. The clinical trial will be carried out in Thailand and is expected to last 5 years. In October 2002, DoD will certainly transfer management of the HIV vaccine trial and research initiative to NIH come comply v direction native the Office of Management and Budget (NIAID, 2002a).


As mentioned above, DoD maintains a unique Immunizations regimen (SIP) within USAMRIID who mission is come “offer FDA licensed vaccines and also investigational new drug (IND) vaccines under educated consent come laboratory workers at USAMRIID, and to other, military, government, or contractor personnel who might be at occupational risk that exposure to extremely hazardous pathogenic microorganisms or toxins” (Boudreau and Kortepeter, 2002). SIP administers 5 FDA-licensed vaccines and nine vaccines v IND status; this are noted in Tables 3-7 and also 3-8, respectively. Table 3-9 list the two vaccines because that which CDC is the IND sponsor yet which SIP administers to the military.

A number of vaccines the DoD has emerged over the years, including the vaccines noted in Table 3-8, have remained at the pilot level the production, through no commercial manufacturers identified. Incentives to pursue full-scale production have been limited primarily because of the geographically restricted nature that the illness that the vaccines were designed come prevent and the minimal commercial potential of these products. DoD encounters obstacles in keeping these products easily accessible to army personnel as soon as the vaccines are needed. Few of the obstacles encountered encompass the difficulties of meeting FDA regulatory requirements, difficulties associated with administering assets with IND status, and the increased price of vaccine development. Significantly, as explained in the keep in mind to Table 3-8, live, attenuated vaccines against chikungunya virus, Junin virus, and also Rift Valley fever virus that were previously obtainable as INDs with SIP no much longer have active IND status and also thus space not accessible even for very devoted uses in ~ DoD.

FDA regulations call for that a organic product it is in evaluated because that its immunogenicity, safety, and also efficacy before licensure. Under current rules, FDA cannot provide a patent to a vaccine that has not been presented to be efficacious and also safe in clinical trials with humans or for which over there is no durable laboratory evidence that indicates that the vaccine offers the same protective immunity demonstrated in previously studies with another vaccine (FDA, 1998). Many of the vaccines the SIP manages are designed to protect against rare infections, herbal occurrences that which room unpredictable in daily settings. To a large extent, that might preclude the opportunity of completing standard clinical efficacy trials v these vaccines. The capability to command experimental difficulty tests is severely restricted or certain prohibited by well-accepted honest rules guiding person experimentation. Therefore, it would certainly be very challenging to fulfill the existing FDA requirements for licensure for these vaccines.

Two FDA rules resolve the challenge of providing sufficient evidence that efficacy because that these vaccines. A ascendancy finalized together the committee completes this report enables the use of data from pet studies as surrogates because that human-study data once it is no feasible to conduct tests through humans. The rule pertains to the constraints on the testing of the efficacy that a vaccine and also does not deal with the requirement to show the safety of the product in large numbers of human beings (FDA, 2002c). A 2nd rule—subpart H: sped up approval of brand-new drugs for major or life-threatening illnesses8 —permits accelerated approval of new drugs for severe or life-threatening illnesses. It claims that “FDA may approve marketing approval because that a brand-new drug product top top the communication of adequate and also well-controlled clinical trials establishing that drug product has actually an result on a surrogate endpoint.”

To detect fairly low frequency adverse events related to vaccine administration, tests should be conducted with an extensive numbers of subjects, make the show of safety and efficacy not only complicated but also costly. Several published approximates from the medicine industry and also others show that about 60 come 75 percent of vaccine breakthrough costs take place in the late phase of product advancement (Greco, 2001; Monath, 2000). These and related issues are discussed further in addition to the recommendations in thing 4.

Current regulations preclude the usage of assets with IND standing without follow to extant regulations applicable come clinical research with experimental products.9 This consists of the entry to FDA of certain information pertaining to the product and also the proposed clinical studies, front approval through an independent institutional evaluation board, the repertoire of informed consent, and also detailed recordkeeping.10 The myriad procedures and documentation steps have the right to be difficult—if not impossible—to adhere to throughout military operations.

In 1990, in ~ the request of DoD, FDA published an interim dominance addressing DoD"s concerns about the use of commodities with IND standing in combat situations. The interim rule allowed the FDA commissioner to waive the notified consent need when such a waiver was requested by the Assistant Secretary of Defense for health Affairs. Application of the dominion was restricted to the “use of one investigational drug (including one antibiotic or biological product) in a particular protocol under an investigational new drug application” and was “limited come a specific military operation including combat or the prompt threat of combat.”11 The ascendancy was used during the Gulf War, permitting the use of pyridostigmine bromide and a botulinum toxoid vaccine come protect against the potential usage of weaponized organic or chemical agents (Rettig, 1999).

When organization members went back from the Gulf battle deployment and also reported medically unexplained symptoms, countless questioned the safety and also efficacy of the vaccine and also drug commodities used throughout the war and also the wisdom the DoD"s use of the interim rule. This perceptions, i beg your pardon may have been different had there to be credible evidence of the actual usage of chemistry or biological weapons by pressures opposing U.S. And also allied personnel, sparked alters in the government"s policy concerning the IND waiver. In part because of concerns that prospered out that the use of the interim dominance during the Gulf War, the U.S. Conference passed one amendment come the Defense Authorization Act for FY 199912 the vests solely with the president the authority to waive the educated consent requirement. Accordingly, FDA revoked the 1990 interim rule and established a brand-new interim final preeminence outlining the minimal circumstances in i m sorry the president could waive the informed consent requirement: “if the President find obtaining informed consent (1) not feasible; (2) contradictory to the best interests that the members; or (3)not in the ideal interests of nationwide security” (FDA, 1999, p. 54181).

DoD to be again criticized because that administering a product through IND condition without close follow to the FDA guidelines when it supplied the tick-borne encephalitis (TBE) vaccine in the Bosnian conflict. For numerous years, the military had administered the TBE vaccine come U.S. Personnel who inspected armed forces sites in the Soviet Union, wherein TBE is endemic. The vaccine, developed by researchers from Austria and also the unified Kingdom, had actually been widely provided in Europe however had no been licensed for usage in the united States. In 1993, the armed Forces Epidemiological plank (AFEB) to be asked to evaluate and make a recommendation about the use of the TBE vaccine (for i m sorry the military held one IND application). AFEB recommended that the vaccine versus TBE be provided “under IND protocol with educated consent” to safeguard military personnel with far-reaching potential for exposure come TBE (AFEB, 1993). In 1996, the Assistant Secretary of Defense for health and wellness Affairs outlined, based on input provided by USAMRMC and also the surgeons general, DoD policy concerning the usage of a vaccine against TBE. The policy instructed the the TBE vaccine need to be readily available to “personnel at really high threat of mite exposure” and that it must not be supplied to on regular basis immunize every DoD personnel (ASD, 1996). DoD readily available the TBE vaccine to soldiers deployed to locations in Bosnia known to be affected by tick-borne encephalitis. To get the vaccine, however, individuals had actually to volunteer to get involved in a study of the IND product and, accordingly, to carry out written informed consent.

An examination by the General accounting Office right into the Army"s recordkeeping practices throughout the Bosnian problem (GAO, 1997) discovered that virtually one-fourth of the immunizations versus TBE in Bosnia to be not correctly documented. FDA, also, discovered “significant deviation” indigenous the guidelines concerned the use of a product v IND standing in DoD"s usage of the TBE vaccine in Bosnia (FDA, 1997b). Back DoD public representative “acknowledged faulty recordkeeping,” they maintained that IND indict were complied with (Gillert, 1998). The TBE vaccine is no longer available to U.S. Military personnel together a product through FDA IND status.

See more: Does Trump Give His Salary Away, Trump Donates Second

The succession of occasions outlined over highlights the obstacles inherent in complying with FDA rules pertained to an IND product and also conducting well-documented clinical trials the investigational vaccines amongst military personnel involved in combat or participating in peacekeeping duties under hazardous conditions. Castle also allude out the obstacles that commanders face as soon as they must face the rules and also regulatory methods that room in place when they are deploying forces into situations that are likely to disclose those pressures to infectious disease threats because that which license is granted vaccines may not it is in available.